Literature DB >> 14568262

Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis.

Bong-Kyeong Oh1, Kwang Jo Chae, Chanil Park, Kyungsik Kim, Woo Jung Lee, Kwang-hyub Han, Young Nyun Park.   

Abstract

BACKGROUNDS/AIMS: The maintenance of telomere with telomerase reactivation, vital for carcinogenesis, was studied in human multistep hepatocarcinogenesis for the characterization of borderline lesions.
METHODS: The terminal restriction fragment length (TRFL) and telomerase activity (TA) were examined in 3 chronic hepatitis (CH), 10 cirrhosis, 7 large regenerative nodules (LRNs), 30 low grade dysplastic nodules (LGDNs), 6 high grade DNs (HGDNs), 3 DNs with hepatocellular carcinoma (HCC) foci, 11 HCCs, and 4 normal livers by Southern hybridization and TRAPeze Elisa telomerase detection.
RESULTS: The TRFL and TA showed significant differences between the LGDNs and HGDNs. Most LGDNs had similar levels of TRFL and TA to those of the CH, cirrhosis and LRNs, however, 17% of LGDNs revealed shortening of telomeres up to the levels of HGDNs and 7% of LGDNs showed high levels of TA. The levels of TRFL and TA in HGDNs showed no significant differences from those of DNs with HCC foci and HCCs.
CONCLUSIONS: The shortening of telomeres and reactivation of telomerase occur in the DNs during the early stages of hepatocarcinogenesis, with a significant change in the transition of LGDNs to HGDNs. The characteristics of HGDNs are considered to be closer to those of HCCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568262     DOI: 10.1016/s0168-8278(03)00395-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

2.  Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Wei Wu; Min Yao; Li-Wei Qiu; Xin-Hua Wu; Xiao-Qin Su; Li Zou; Deng-Bing Yao; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis.

Authors:  D Heim; K Cornils; K Schulze; B Fehse; A W Lohse; T H Brümmendorf; H Wege
Journal:  Oncogene       Date:  2014-01-13       Impact factor: 9.867

Review 4.  Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target.

Authors:  Yuting Wu; Xiaoming Meng; Cheng Huang; Jun Li
Journal:  Tumour Biol       Date:  2015-05-01

5.  Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis.

Authors:  Bong-Kyeong Oh; Young-Joo Kim; Chanil Park; Young Nyun Park
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  Telomere Length and Risk of Hepatocellular Carcinoma: A Nested Case-control Study in Taiwan Cancer Screening Program Cohort.

Authors:  Hui Zeng; Hui-Chen Wu; Qiao Wang; Hwai-I Yang; Chien-Jen Chen; Regina M Santella; Jing Shen
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

7.  Telomere length and pancreatic cancer: a case-control study.

Authors:  Halcyon G Skinner; Ronald E Gangnon; Kristin Litzelman; Ruth A Johnson; Suresh T Chari; Gloria M Petersen; Lisa A Boardman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-23       Impact factor: 4.254

Review 8.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

9.  Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States.

Authors:  Baiyu Yang; Fatma M Shebl; Lawrence R Sternberg; Andrew C Warner; David E Kleiner; Daniel C Edelman; Allison Gomez; Casey L Dagnall; Belynda D Hicks; Sean F Altekruse; Brenda Y Hernandez; Charles F Lynch; Paul S Meltzer; Katherine A McGlynn
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

Review 10.  Telomeres, NAFLD and Chronic Liver Disease.

Authors:  Benedetta Donati; Luca Valenti
Journal:  Int J Mol Sci       Date:  2016-03-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.